Tuscanstar Pharmaceuticals. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders. Promentis’ drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other diseases. company profile
The New York Academy of Sciences sponsored a conference, Advancing Drug Discovery for Schizophrenia, to bring scientists and clinicians together to present innovative pharmacological agents for the treatment of schizophrenia. Dr. Baker presented findings at this conference suggesting the antipsychotic potential of agents that target a novel mechanism within the glutamate system. . view article
Biotechnology comes today.
Tuscanstar Pharmaceuticals drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other diseases.
"Tuscan Pharmaceuticals, Inc. is exactly the type of company our state should be investing in..."
. Invester Inquiries
"Tuscanstar Pharmaceuticals, Inc. are developing innovative solutions in the biotechnology industry. I am pleased we can assist this company in its growth and development."